home / stock / gnca / gnca news


GNCA News and Press, Genocea Biosciences Inc. From 07/08/19

Stock Information

Company Name: Genocea Biosciences Inc.
Stock Symbol: GNCA
Market: NASDAQ

Menu

GNCA GNCA Quote GNCA Short GNCA News GNCA Articles GNCA Message Board
Get GNCA Alerts

News, Short Squeeze, Breakout and More Instantly...

GNCA - OASM, BLCM among premarket gainers

Oasmia Pharmaceutical AB (NASDAQ: OASM ) +22% . More news on: Oasmia Pharmaceutical AB (publ), Sangamo Therapeutics, Inc., Aytu BioScience, Inc., Stocks on the move, Read more ...

GNCA - Daily Insider Ratings Round Up 6/26/19

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

GNCA - Daily Insider Ratings Round Up 6/25/19

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

GNCA - CCL, DRI and SCS among premarket losers

Scholar Rock Holding (NASDAQ: SRRK )  -11%  on pricing share offering. More news on: Scholar Rock Holding Corporation, Carnival plc, Carnival Corporation, Stocks on the move, Read more ...

GNCA - Genocea prices stock offering

Genocea Biosciences (NASDAQ: GNCA ) has priced its public offering of 10.5M common shares at $3.50/share, for gross proceeds of $36.75M. More news on: Genocea Biosciences, Inc., Healthcare stocks news, Read more ...

GNCA - Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock

CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the pricing of its previously announced underwritten public offering of 10,500,000 shares of its comm...

GNCA - Analysis Of Genocea's Therapeutic Herpes Vaccine

In my previous Genocea ( GNCA ) article , I initially expressed my belief therapeutic herpes simplex vaccine GEN-003 produced mixed results and wouldn't enter Phase 3 clinical studies. Due to objections from readers, I edited my article eliminating my opinion because to defend it would requir...

GNCA - Healthcare dominate midday movers

Gainers:  Melinta Therapeutics (NASDAQ: MLNT ) +180% . Arcturus Therapeutics (NASDAQ: ARCT ) +37% . Hebron Technology (NASDAQ: HEBT ) +26% . MYOS RENS Technology (NASDAQ: MYOS ) +22% . Armata Pharmaceuticals (NYSEMKT: ARMP ) +19% . AquaBounty Technologies (NASDAQ: AQB ) +19% . D...

GNCA - SESN and KURA among premarket losers

Sesen Bio (NASDAQ: SESN )  -32%  on pricing equity offering. More news on: Sesen Bio, Inc., Tonix Pharmaceuticals Holding Corp., Calithera Biosciences, Inc., Stocks on the move, Read more ...

GNCA - Genocea Biosciences dips ~5% on secondary offering

Genocea Biosciences (NASDAQ: GNCA ) down  5.1%  AH, as the company commenced public offering of 10M. More news on: Genocea Biosciences, Inc., Healthcare stocks news, Read more ...

Previous 10 Next 10